Emerging biological roles for erythropoietin in the nervous system
The DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index.
Abstract
Erythropoietin mediates an evolutionarily conserved, ancient immune response that limits damage to the heart, the nervous system and other tissues following injury. New evidence indicates that erythropoietin specifically prevents the destruction of viable tissue surrounding the site of an injury by signalling through a non-haematopoietic receptor. Engineered derivatives of erythropoietin that have a high affinity for this receptor have been developed, and these show robust tissue-protective effects in diverse preclinical models without stimulating erythropoiesis. A recent successful proof-of-concept clinical trial that used erythropoietin to treat human patients who had suffered a stroke encourages the evaluation of both this cytokine and non-erythropoietic derivatives as therapeutic agents to limit tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Erythropoietin was originally recognized via its role in erythropoiesis [2145-2147] (hence its name, of course), but it has become evident that it has many other roles, and in particular it is observed phenomenologically that erythropoietin (and non-erthyropoetic derivatives) is protective in a number of inflammatory conditions that accompany many diseases such as those listed above [940,942,2148-”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [2150]
Citations
Cites
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., Itri, L. M., & Cerami, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10526 · Cited by 1,402 · cited 1×
“Follow-up studies confirmed erythropoietin to be a neuroprotective factor in hypoxic-ischaemic, traumatic, excitotoxic and inflammatory injurie”
BackgroundSelf-citationHIF-1 and mechanisms of hypoxia sensing
Semenza, G. L. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00194-0 · Cited by 1,268
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250 · cited 1×
“It is worrying that some cancer patients treated with rhEPO have also shown tumour expansio”
BackgroundErythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.-H., Breiter, N., Jacob, S., Knerlich, F., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402029 · Cited by 1,028
Self-citationJuhaszova, M., Zorov, D. B., Kim, S.-H., Pepe, S., Fu, Q., Fishbein, K. W., Ziman, B. D., Wang, S., Ytrehus, K., Antos, C. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19906 · Cited by 1,026
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
Sirén, A.-L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, P., Keenan, S., Gleiter, C., Pasquali, C., Capobianco, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051606598 · Cited by 1,019
Self-citationIn vivo evidence that erythropoietin protects neurons from ischemic damage
Sakanaka, M., Wen, T.-C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M., & Sasaki, R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4635 · Cited by 949 · cited 1×
“Follow-up studies confirmed erythropoietin to be a neuroprotective factor in hypoxic-ischaemic, traumatic, excitotoxic and inflammatory injurie”
BackgroundDigicaylioglu, M., & Lipton, S. A. (2001) · Nature · doi:10.1038/35088074 · Cited by 923 · cited 1×
“Furthermore, although it has been reported that STAT is part of erythropoietin's neuroprotective signalling cascade in vitro , in vivo studies largely have not supported the involvement of STATs in erythropoietin cytoprotectio”
BackgroundPurification of human erythropoietin.
Miyake, T., Kung, C. K., & Goldwasser, E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)63387-9 · Cited by 886
Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic
Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Bianchi, M., Nielsen, J., Gerwien, J., et al. (2004) · Science · doi:10.1126/science.1098313 · Cited by 803
Self-citation
Cited by
Items 101–200 of 527
Sex-dependent regulation of hypoxic ventilation in mice and humans is mediated by erythropoietin
Soliz, J., Thomsen, J. J., Soulage, C. O., Lundby, C., & Gassmann, M. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90967.2008 · Cited by 66
“F: hypoxia was achieved in 2 steps of 15 min-gradual reduction of FIO2 (represented by 9); first step from 21% to 10% O2 and second step from 10% to 6% O2.”
BackgroundMethodInfluentialNeuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor
Pankratova, S., Kiryushko, D., Sonn, K., Soroka, V., Køhler, L. B., Rathje, M., Gu, B., Gotfryd, K., Clausen, O., Zharkovsky, A., et al. (2010) · Brain · doi:10.1093/brain/awq101 · Cited by 65
“signalling molecules such as Stat5 (Brines and Cerami, 2005).”
InfluentialGarcía-Rodríguez, J. C., & Sosa Teste, I. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.103 · Cited by 65
Kirkeby, A., van Beek, J., Nielsen, J., Leist, M., & Helboe, L. (2007) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2007.03.026 · Cited by 65
Pathogenesis of Acute Kidney Injury: Foundation for Clinical Practice
Kinsey, G. R., & Okusa, M. D. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.02.385 · Cited by 64
Wang, Q., Pfister, F., Dorn‐Beineke, A., Hagen, F. V., Lin, J., Feng, Y., & Hammes, H. (2010) · Diabetologia · doi:10.1007/s00125-010-1727-7 · Cited by 63
New horizons in prevention and treatment of ischaemic injury to kidney transplants
Aydin, Z., van Zonneveld, A. J., de Fijter, J. W., & Rabelink, T. J. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl690 · Cited by 62
Rah, W.-J., Lee, Y. H., Moon, J., Jun, H.-J., Kang, H.-R., Koh, H., Eom, H. J., Lee, J. Y., Lee, Y. J., Kim, J. Y., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1120-0 · Cited by 61
Guan, Y., Cui, L., Qu, Z., Lü, L., Wang, F., Wu, Y., Zhang, J., Gao, F.-L., Tian, H., Xu, L., et al. (2013) · Current Molecular Medicine · doi:10.2174/15665240113139990071 · Cited by 65
“EPO has been reported to have neurotrophic effect on matured CNS neurons which have limited intrinsic growth capacity [30-32].”
BackgroundThe role of aquaporin 4 in the brain
Iacovetta, C., Rudloff, E., & Kirby, R. (2012) · Veterinary Clinical Pathology · doi:10.1111/j.1939-165x.2011.00390.x · Cited by 69
Erythropoietin enhances immune responses in mice
Katz, O., Gil, L., Lifshitz, L., Prutchi‐Sagiv, S., Gassmann, M., Mittelman, M., & Neumann, D. (2007) · European Journal of Immunology · doi:10.1002/eji.200637025 · Cited by 58
Erythropoietin and Nrf2: key factors in the neuroprotection provided by apo-lactoferrin
Zakharova, E. T., Av, S., Павличенко, Н. Н., Kostevich, V. A., Abdurasulova, I. N., Владимирович, Ч. А., Voynova, I. V., Elizarova, A. Y., Kolmakov, N. N., Bass, M. G., et al. (2018) · BioMetals · doi:10.1007/s10534-018-0111-9 · Cited by 62
Miskowiak, K., Inkster, B., O’Sullivan, U., Selvaraj, S., Goodwin, G. M., & Harmer, C. J. (2008) · Experimental Brain Research · doi:10.1007/s00221-007-1102-1 · Cited by 59
Neural differentiation of rat aorta pericyte cells
Montiel‐Eulefi, E., Nery, A. A., Rodrigues, L. C., Sánchez, R., Romero, F., & Ulrich, H. (2011) · Cytometry Part A · doi:10.1002/cyto.a.21152 · Cited by 61
Gomes, C., Escrevente, C., & Costa, J. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.03.065 · Cited by 66
Erythropoietin improves operant conditioning and stability of cognitive performance in mice
El-Kordi, A., Radyushkin, K., & Ehrenreich, H. (2009) · BMC Biology · doi:10.1186/1741-7007-7-37 · Cited by 59
Kang, Y., Digicaylioglu, M. H., Russo, R., Kaul, M., Achim, C. L., Fletcher, L., Masliah, E., & Lipton, S. A. (2010) · Annals of Neurology · doi:10.1002/ana.22070 · Cited by 58
Carbamylated Erythropoietin Reduces Radiosurgically-Induced Brain Injury
Erbayraktar, S., de Lanerolle, N. C., de Lotbinière, A., Knisely, J. P. S., Erbayraktar, Z., Yılmaz, O., Cerami, A., Coleman, T. R., & Brines, M. L. (2006) · Molecular Medicine · doi:10.2119/2006-00042.erbayraktar · Cited by 58
Self-citationNon-erythroid activities of erythropoietin: Functional effects on murine dendritic cells
Lifshitz, L., Prutchi‐Sagiv, S., Avneon, M., Gassmann, M., Mittelman, M., & Neumann, D. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.10.004 · Cited by 59
The Potential Roles of Aquaporin 4 in Alzheimer’s Disease
Lan, Y., Zhao, J., Ma, T., & Li, S. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9446-1 · Cited by 62
Miskowiak, K. W., Favaron, E., Hafizi, S., Inkster, B., Goodwin, G. M., Cowen, P. J., & Harmer, C. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1641-1 · Cited by 58
Prutchi‐Sagiv, S., Golishevsky, N., Oster, H. S., Katz, O., Cohen, A., Naparstek, E., Neumann, D., & Mittelman, M. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06366.x · Cited by 56
Tumor Necrosis Factor α Primes Cerebral Endothelial Cells for Erythropoietin-Induced Angiogenesis
Wang, L., Chopp, M., Teng, H., Bolz, M., Moniche, F., Aluigi, D. M., Wang, X. L., Zhang, R. L., Chrsitensen, S., Sager, T. N., et al. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.138 · Cited by 57
“The observed distinct effect of rhEPO and CEPO on the TNF-treated endothelial cells suggests that TNF/TNFR1 primes cerebral endothelial cells for EPO-induced angiogenesis through upregulation of the EPOR homodimer in cerebral endothelial cells, which is consistent with the view that endothelial cells predominantly exp…”
BackgroundInfluentialWestenbrink, B. D., Oeseburg, H., Kleijn, L., van der Harst, P., Belonje, A. M. S., Voors, A. A., Schoemaker, R. G., de Boer, R. A., van Veldhuisen, D. J., & van Gilst, W. H. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6094-y · Cited by 60
Ureña‐Guerrero, M. E., Castañeda‐Cabral, J. L., Rivera-Cervantes, M. C., Vélez, R., Jarero-Basulto, J. J., Gudiño‐Cabrera, G., & Beas‐Zárate, C. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200114104342 · Cited by 57
Recombinant Human Erythropoietin in the Treatment of Human Brain Disease: Focus on Cognition
Ehrenreich, H., Bartels, C., Sargin, D., Stawicki, S., & Krampe, H. (2007) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2007.10.029 · Cited by 54
Gene Therapy of Inherited Retinopathies: A Long and Successful Road from Viral Vectors to Patients
Colella, P., & Auricchio, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.123 · Cited by 50
Schreiber, K. I., Magyari, M., Sellebjerg, F. T., Iversen, P., Garde, E., Madsen, C. G., Börnsen, L. S., Christensen, J. R., Ratzer, R. L., Siebner, H. R., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516661048 · Cited by 54
Chang, R., Maghribi, A. A., Vanderpoel, V., Vasilevko, V., Cribbs, D. H., Boado, R. J., Pardridge, W. M., & Sumbria, R. K. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00594 · Cited by 57
Hippocampal neurons respond to brain activity with functional hypoxia
Butt, U. J., Steixner-Kumar, A. A., Depp, C., Sun, T., Hassouna, I. A., Wüstefeld, L., Arinrad, S., Zillmann, M. R., Schopf, N., Garcia‐Agudo, L. F., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00988-w · Cited by 58
Adamcio, B., Sperling, S., Hagemeyer, N., Walkinshaw, G., & Ehrenreich, H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.11.010 · Cited by 57
Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Merelli, A., Czornyj, L. A., & Lazarowski, A. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319380011 · Cited by 61
Erythropoietin Pathway: A Potential Target for the Treatment of Depression
Ma, C., Cheng, F., Wang, X., Zhai, C., Yue, W., Lian, Y., & Wang, Q. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050677 · Cited by 56
Epo and Non-hematopoietic Cells: What Do We Know?
Ogunshola, O. O., & Bogdanova, A. Y. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-308-4_2 · Cited by 60
Miskowiak, K. W., O’Sullivan, U., & Harmer, C. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.011 · Cited by 55
Effects of erythropoietin on the bone microenvironment
McGee, S., Havens, A. M., Shiozawa, Y., Jung, Y., & Taichman, R. S. (2011) · Growth Factors · doi:10.3109/08977194.2011.637034 · Cited by 54
Miskowiak, K. W., Vinberg, M., Harmer, C. J., Ehrenreich, H., Knudsen, G. M., Macoveanu, J., Hansen, A. R., Paulson, O. B., Siebner, H. R., & Kessing, L. V. (2010) · Trials · doi:10.1186/1745-6215-11-97 · Cited by 51
Can erythropoietin be used to prevent brain damage in cerebral malaria?
Casals‐Pascual, C., Idro, R., Picot, S., Roberts, D. J., & Newton, C. R. J. C. (2008) · Trends in Parasitology · doi:10.1016/j.pt.2008.10.002 · Cited by 55
Epo and other hematopoietic factors
Juul, S. E., & Felderhoff‐Mueser, U. (2007) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2007.01.015 · Cited by 51
Artesunate–erythropoietin combination for murine cerebral malaria treatment
Bienvenu, A., Ferrandiz, J., Kaiser, K., Latour, C., & Picot, S. (2008) · Acta Tropica · doi:10.1016/j.actatropica.2008.02.001 · Cited by 53
“Since Epo and Epo-receptor are expressed in several organs (including kidney, brain, heart, muscle, endothelial cells), Epo function is not limited to the hematopoietic system (Brines and Cerami, 2005).”
BackgroundZhang, F., Xing, J., Liou, A. K. F., Wang, S., Gan, Y., Luo, Y., Ji, X., Stetler, R. A., Chen, J., & Cao, G. (2010) · Translational Stroke Research · doi:10.1007/s12975-010-0019-3 · Cited by 51
General Anesthetics Inhibit Erythropoietin Induction under Hypoxic Conditions in the Mouse Brain
Tanaka, T., Kai, S., Koyama, T., Daijo, H., Adachi, T., Fukuda, K., & Hirota, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029378 · Cited by 51
Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model
Grünfeld, J., Barhum, Y., Blondheim-Shraga, N., Rabey, J.-M., Melamed, E., & Offen, D. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.11.002 · Cited by 53
Erythropoietin: still on the neuroprotection road
Subirós, N., del Barco, D. G., & Coro-Antich, R. M. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611434926 · Cited by 53
“There are several in vitro and in vivo studies reporting neuroprotective effects of EPO [Brines and Cerami, 2005; Genc et al. 2004; Marti, 2004].”
BackgroundSafety of epoietin beta-quinine drug combination in children with cerebral malaria in Mali
Picot, S., Bienvenu, A., Konaté, S., Sissoko, S., Barry, A., Diarra, E., Bamba, K., DJIMDÉ, A. A., & Doumbo, O. K. (2009) · Malaria Journal · doi:10.1186/1475-2875-8-169 · Cited by 50
TNF-alpha-induced apoptosis is prevented by erythropoietin treatment on SH-SY5Y cells
Pregi, N., Wenker, S. D., Vittori, D. C., Leirós, C. P., & Nesse, A. B. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.11.005 · Cited by 48
EPO: renoprotection beyond anemia correction
Fliser, D., Bahlmann, F. H., & Haller, H. G. (2006) · Pediatric Nephrology · doi:10.1007/s00467-006-0284-2 · Cited by 48
Erythropoietin promotes survival and regeneration of insect neurons in vivo and in vitro
Ostrowski, D., Ehrenreich, H., & Heinrich, R. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.05.018 · Cited by 47
Okada, T., Sawada, T., & Kubota, K. (2007) · Transplantation · doi:10.1097/01.tp.0000277672.02783.33 · Cited by 47
Genç, K., Eğrilmez, M. Y., & Genç, Ş. (2010) · Cell Biochemistry and Function · doi:10.1002/cbf.1639 · Cited by 46
MIF: Mood Improving/Inhibiting Factor?
Bloom, J., & Al‐Abed, Y. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-11 · Cited by 49
Schmeer, C. W., Kretz, A., & Isenmann, S. (2006) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-2006-00333 · Cited by 52
Granulocyte-colony stimulating factor (G-CSF) and G-CSF receptor expression in human ischemic stroke
Hasselblatt, M., Jeibmann, A., Riesmeier, B., Maintz, D. C., & Schäbitz, W. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0152-y · Cited by 45
“The discovery that the hematopoietic growth factors erythropoietin and granulocyte-colony stimulating factor (G-CSF) and their respective receptors are also expressed in the brain and exert neuroprotective properties [2, 16] has fueled hope that hematopoietic growth factors might once successfully complement multimoda…”
BackgroundBailey, D. M., Lundby, C., Berg, R. M. G., Taudorf, S., Rahmouni, H., Gutowski, M., Mulholland, C. W., Sullivan, J. L., Swenson, E. R., McEneny, J., et al. (2014) · Acta Physiologica · doi:10.1111/apha.12313 · Cited by 46
Erythropoietin: A Candidate Neuroprotective Agent in the Treatment of Glaucoma
Tsai, J. C., Song, B. J., Wu, L., & Forbes, M. (2007) · Journal of Glaucoma · doi:10.1097/ijg.0b013e318156a556 · Cited by 45
Cardiovascular Effects of Erythropoietin
Santhanam, A. V. R., d’Uscio, L. V., & Katušić, Z. S. (2010) · Advances in pharmacology · doi:10.1016/b978-0-12-385061-4.00009-x · Cited by 44
Peripheral neuropathy in sarcoidosis
Tavee, J. O. (2022) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2022.577864 · Cited by 45
Xing, C., Lee, S.-R., Kim, W. J., Wang, H., Yang, Y., Ning, M., Wang, X., & Lo, E. H. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22076 · Cited by 44
Faure, S., Oudart, N., Javellaud, J., Fournier, A. E., Warnock, D. G., & Achard, J. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249704.34607.4c · Cited by 44
Prolyl-4-hydroxylase 2 and 3 coregulate murine erythropoietin in brain pericytes
Urrutia, A. A., Afzal, A., Nelson, J., Davidoff, O., Gross, K. W., & Haase, V. H. (2016) · Blood · doi:10.1182/blood-2016-05-713545 · Cited by 48
Erythropoietic and non‐erythropoietic functions of erythropoietin in mouse models
Vogel, J., & Gassmann, M. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2010.196147 · Cited by 43
Gray Matter Volumetric Abnormalities Associated with the Onset of Psychosis
Jung, W. H., Borgwardt, S., Fusar‐Poli, P., & Kwon, J. S. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00101 · Cited by 46
Liu, Y., Luo, B., Shi, R., Wang, J., Liu, Z., Liu, W. Y., Wang, S., & Zhang, Z. (2015) · Scientific Reports · doi:10.1038/srep15134 · Cited by 45
Rey, F., Ottolenghi, S., Giallongo, T., Balsari, A., Martinelli, C., Rey, R., Allevi, R., Giulio, A. M. D., Zuccotti, G., Mazzucchelli, S., et al. (2021) · Antioxidants · doi:10.3390/antiox10010121 · Cited by 45
Erythropoietin promotes hippocampal mitochondrial function and enhances cognition in mice
Jacobs, R. A., Aboouf, M. A., Köster-Hegmann, C., Muttathukunnel, P., Laouafa, S., Arias‐Reyes, C., Thiersch, M., Soliz, J., Gassmann, M., & Gasser, E. M. S. (2021) · Communications Biology · doi:10.1038/s42003-021-02465-8 · Cited by 44
Bader, A., Lorenz, K., Richter, A. M., Scheffler, K., Kern, L., Ebert, S., Giri, S., Behrens, M., Dornseifer, U., Macchiarini, P., et al. (2011) · Rejuvenation Research · doi:10.1089/rej.2010.1050 · Cited by 47
Neurite outgrowth on cultured spiral ganglion neurons induced by erythropoietin
Berkingali, N., Warnecke, A., Gomes, P. M., Paasche, G., Tack, J. F., Lenarz, T., & Stöver, T. (2008) · Hearing Research · doi:10.1016/j.heares.2008.07.003 · Cited by 43
Kanaan, N. M., Collier, T. J., Marchionini, D. M., McGuire, S. O., Fleming, M. F., & Sortwell, C. E. (2005) · Brain Research · doi:10.1016/j.brainres.2005.10.078 · Cited by 43
Krügel, K., Wurm, A., Linnertz, R., Pannicke, T., Wiedemann, P., Reichenbach, A., & Bringmann, A. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.11.035 · Cited by 42
Fukuta, T., Oku, N., & Kogure, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020361 · Cited by 42
Mausberg, A. K., zu Hörste, G. M., Dehmel, T., Stettner, M., Lehmann, H. C., Sheikh, K. A., & Kieseier, B. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026280 · Cited by 42
Just, N., Moreau, C., Lassalle, P., Gosset, P., Perez, T., Danel-Brunaud, V., Wallaert, B., Destée, A., Defebvre, L., Tonnel, A., et al. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.10.004 · Cited by 42
“Over recent years, it has become increasingly clear that in addition to its role in erythropoiesis, erythropoietin (EPO) exerts neuroprotective effects following the occurrence of ischemic, hypoxic, metabolic, neurotoxic or excitotoxic stress in the central nervous system (CNS) [9–12].”
BackgroundInfluentialSanthanam, A. V. R., Smith, L. A., Nath, K. A., & Katušić, Z. S. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00045.2006 · Cited by 42
“Recently, several studies have demonstrated a significant neuroprotective effect of Epo and its nonhematopoietic derivatives (9, 17, 20, 27), and a proof of concept clinical trial demonstrated beneficial effects of Epo in patients with an acute stroke (16).”
BackgroundAntidepressant-Like Effects of Erythropoietin: A Focus on Behavioural and Hippocampal Processes
Osborn, M., Rustom, N., Clarke, M., Litteljohn, D., Rudyk, C., Anisman, H., & Hayley, S. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072813 · Cited by 47
Kästner, A., Grube, S., El-Kordi, A., Stepniak, B., Friedrichs, H., Sargin, D., Schwitulla, J., Begemann, M., Giegling, I., Miskowiak, K. W., et al. (2012) · Molecular Medicine · doi:10.2119/molmed.2012.00190 · Cited by 41
Erythropoietin inhibits cytokine production of neonatal and adult leukocytes
Strunk, T., Härtel, C., Ketteler, P., Matzke, N., Zimmer, J., & Schultz, C. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00560.x · Cited by 42
Colella, P., Iodice, C., Vicino, U. D., Annunziata, I., Surace, E. M., & Auricchio, A. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr115 · Cited by 41
Miskowiak, K. W., Favaron, E., Hafizi, S., Inkster, B., Goodwin, G. M., Cowen, P. J., & Harmer, C. J. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1842-7 · Cited by 40
Gobe, G. C., Bennett, N. J., West, M., Colditz, P. B., Brown, L., Vesey, D. A., & Johnson, D. W. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00241.2013 · Cited by 43
Schmidt, R. E., Green, K. G., Feng, D., Dorsey, D. A., Parvin, C. A., Lee, J., Xiao, Q., & Brines, M. L. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.09.018 · Cited by 40
Self-citationErythropoietin and soluble CD44 levels in patients with primary open‐angle glaucoma
Mokbel, T. H., Ghanem, A. A., Kishk, H., Arafa, L. F., & El-Baiomy, A. A. (2010) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2010.02318.x · Cited by 40
Effect of erythropoietin on oxygen-induced brain injury in the newborn rat
Yiş, U., Kurul, S. H., Kumral, A., Tuğyan, K., Cilaker, S., Yılmaz, O., Genç, Ş., & Genç, K. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.10.060 · Cited by 40
Erythropoietin and Treatment of Non-anemic Conditions—Cardiovascular Protection
Fliser, D., & Haller, H. G. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.04.008 · Cited by 40
Ishii, T., Asai, T., Fukuta, T., Oyama, D., Yasuda, N., Agato, Y., Shimizu, K., Minamino, T., & Oku, N. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.09.026 · Cited by 40
Miljus, N., Heibeck, S., Jarrar, M., Micke, M., Ostrowski, D., Ehrenreich, H., & Heinrich, R. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.11.020 · Cited by 43
Sorg, H., Harder, Y., Krueger, C., Reimers, K., & Vogt, P. M. (2012) · Medicinal Research Reviews · doi:10.1002/med.21259 · Cited by 42
Erythropoietin drives breast cancer progression by activation of its receptor EPOR
Chan, K. K., Matchett, K. B., Coulter, J. A., Yuen, H., McCrudden, C. M., Zhang, S., Irwin, G. W., Davidson, M. A., Rülicke, T., Schober, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16368 · Cited by 41
Going High with Preexisting Neurological Conditions
Baumgartner, R. W., Siegel, A. M., & Hackett, P. H. (2007) · High Altitude Medicine & Biology · doi:10.1089/ham.2006.1070 · Cited by 39
Schuler, B., Vogel, J., Grenacher, B., Jacobs, R. A., Arras, M., & Gassmann, M. (2012) · The FASEB Journal · doi:10.1096/fj.11-191197 · Cited by 39
Bernhardt, W. M., & Eckardt, K. (2008) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e328317ee82 · Cited by 38
Mouri, A., Nagai, T., Ibi, D., & Yamada, K. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.025 · Cited by 40
Robinson, S., Winer, J. L., Berkner, J., Chan, L. A. S., Denson, J. L., Maxwell, J. R., Yang, Y., Sillerud, L. O., Tasker, R. C., Meehan, W. P., III, et al. (2016) · Journal of Neurosurgery Pediatrics · doi:10.3171/2015.10.peds15554 · Cited by 40
Beyond erythropoiesis: The anti-inflammatory effects of erythropoietin
Feng, Q. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.07.001 · Cited by 38
Yoo, S., Cho, B., Lee, D., Son, G., Lee, Y., Han, H. S., Kim, E., Moon, C., & Moon, C. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.381 · Cited by 37
Lee, J. I., Hur, J. M., You, J., & Lee, D. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238208 · Cited by 37
“EPORs are expressed in the central nervous system and on the myelin sheath of radicular nerves in humans [45, 46].”
BackgroundHuntemann, N., Rolfes, L., Pawlitzki, M., Ruck, T., Pfeuffer, S., Wiendl, H., & Meuth, S. G. (2021) · Drugs · doi:10.1007/s40265-021-01526-w · Cited by 36
The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review
Ma, Y., Zhou, Z., Yang, G., Ding, J., & Wang, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.743926 · Cited by 37
Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?
Latini, R., Brines, M. L., & Fiordaliso, F. (2008) · Heart Failure Reviews · doi:10.1007/s10741-008-9084-z · Cited by 44
“EPO and its nonerythropoietic derivatives have potent anti-inflammatory effects [ 1 ], including the heart subjected to ischemiareperfusion [39].”
BackgroundSelf-citationMechanisms of Disease: erythropoietin—an old hormone with a new mission?
Fliser, D., Bahlmann, F. H., deGroot, K., & Haller, H. G. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0609 · Cited by 37
“We will not discuss the broad field of neuroprotection, since several excellent review articles have been published on this issue recently”
BackgroundPhan, V. H. G., Duong, H. S., Le, Q.-G. T., Janarthanan, G., Vijayavenkataraman, S., Nguyen, H.-N. H., Nguyen, B.-P. T., Manivasagan, P., Jang, E., Li, Y., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02160-2 · Cited by 36
Metadata
- Authors
- Brines, M., & Cerami, A.
- Corresponding author
- Brines, Michael
- Venue
- Nature Reviews Neuroscience
- Published
- 2005-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 484-494
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2168867226
- Cited by
- 523
- References
- 108
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 6 · 2023: 8 · 2022: 18 · 2021: 21 · 2020: 13 · 2019: 25 · 2018: 17 · 2017: 16 · 2016: 21 · 2015: 19 · 2014: 22 · 2013: 30 · 2012: 38
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Update notices
- correction (2005-08-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- www.springer.com/tdm (unspecified)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heme Oxygenase-1 and Carbon Monoxide
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- erythropoietin, nervous system, neuroprotection, tissue damage, stroke, neuroinflammation
- MeSH terms
- Animals, Central Nervous System, Erythropoietin, Humans, Signal Transduction, Receptors, Cytokine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.